Ticker Symbol (OTCQB) “MYDX”
Fiscal Year
Recent price
Market Cap
Insider Ownership
Shares Out (May 17, 2016)
MyDx, In
and tec c. (OTCQB: MYD
h
X
duces a nology compa ) is a science
ny that
nd mark
prooperate
ets the
fi
d
ical ana , multi-use han rst battery
ly
d
ed MyD zer for consum held chemx™ (My
e
Diagno rs. Its patentline is co
stic) pro
m
p
r
is
ed
du
that con
nects via of the MyDx de ct
phone a
vice
B
lu
etoo
p
effect o p to analyze th th to a smart
f
e
and inh what consume chemical
ale (see
rs eat, d
: www.c
r
cdxshop
dxlife.co ink
).
m/
MyDx e
x
in 2016 pects to reach
. The My
p
Dx analy rofitability
for $699
z
a
n
(analyze d includes th er retails
r and se
e hardw
app and
nsor), sm
are
It is mult one-time dispo art phone
s
change i-use and hous able inserts.
es inter
able sen
sors for
plicatio
n
d
By conn s (cannabis, wa ifferent apt
e
smartph cting to its An er, food, air).
droid or
one My
iOS
crowd-s
Dx app,
o
it
US sales urced cloud-b leverages a
a
first ma are expected to sed database.
jor distr
ibution jump as its
effect in
deal tak
t
h
e
curr
e
al sales
are dive ent quarter. Glo s
rse and
estimat
es.
exceedin bg
Dec. 31
$0.18
$4 million
47%
22.2M
The Ana
lyz
starting er has a blend
ed gros
at abou
s
t 50% a
scale wit
nd is ex margin
h highe
pected
r volum
is now p
to
es th
reparing
to manu e Company
MyDx A
nalyzer
fa
c
ture. Th
requires
“sample
e
one
in
and pro serts,” that are p -time use
vid
ric
with gro e a recurring re ed at $1.29
venue s
ss marg
tream
ins of ap
Additio
pro
nall
revenue y, the Compan ximately 80%.
y genera
on prem
tes
ium wa
ancillary
rranties
sales.
and oth
er
The San
Diego-b
ased Co
its first p
mpany
roduct s
lau
ensor, C
2015 to
annaDx nched
address
TM, in la
the exp
the can
te
losive g
nab
rowth in
ers to aff is market and
enable
ordably
consum
identify
compos
the che
ition of
Goals an
mical
cannab
MyDx H
care. A J
d Ca
is at the
une 201
i
g
•U
In
h
n
p
creasing talysts for Expo
l
iq
o
i
5
int of
g
ue, Nex
of the A
study in
h
t
s
n
Earning
t-Genera
merican
the Jou
s Power entially
tion Han
rnal
Medica
75 edib
in
clude:
l
d
A
le canna
-held Te
1) Cann
bis prod ssociation of
chaDX: Th
83% of
ucts sold
e
them m
m
•A
U
S canna
arket is
ddresse
nology
islabele
MyDx a
b
forecast
s Multid the TH found
lso has
billion d
million
to reach is testing
C
th
b
c
o
o
re
y
$
ll
comme
n
800 to $
2
a
e
te
r
0
n
2
G
n
e
0
lo
t.
w
bal Marrcializati
sensors
900
on
in
pesticid
2
)
M
es in foo pipeline for an its
ajor Nan
k
e
ts
a
d, chem
olux Te
toxins in
bution d
•First-M
icals in w lyzing
the air.
eal (targ ch - CannaDx
over Ad
ater, an
•Unrivall
dis
v
ets grow
v
a
a
n
d
lued at
ed Com
tage
ers) sign tri$4M+
petitive
ed Q2
Advanta
ges, Ma
3) Upgra
rket
ded ma
Leaders
•Valuab
nufactu
c
hain
h
ip
le, Grow
ring and
ing, Inte
supply
llectual
Propert
4
)
L
a
u
y
nch
•Patente
Portfoli
differen three new sens
d, IP, Ere
o
t, multio
cts High
billion d rs that address
markets
Barriers
ollar glo
to Entry
bal
•Veteran
Industry
5
)
M
S
a
te
nageme
ep reve
•Solid G
nt Team
nue ram
ross Ma
p startin
rgins th
g Q3-16
at Scale
6) Num
erous U
with Vo
S States
lume
atives to
have ba
le
llot initipot in N galize medical
or recre
ovembe
ational
r
7) Led b
Phil Sugarman, VP Investor Relations
yC
Pfizer Sc EO Daniel Yazb
(818) 280-6800
e
ientist a
nd Mark ck, former
Panason
et Deve
[email protected]
ic.
loper to
This document contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities
Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this document that are not statements of historical fact may be considered to be
forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but
not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product
testing and launch our product commercially, the acceptance of our product in the marketplace and other uncertainties detailed from time to time in our reports filed with the
Securities and Exchange Commission, available at www.sec.gov.
CANNAINVESTOR Magazine